Latanoprost/Timolol Elvim

Timolol maleate, the active ingredient in Latanoprost/Timolol Elvim, is a prostaglandin analog and beta‑adrenergic blocker presented as eye drops for ocular use. It treats open‑angle glaucoma and ocular hypertension by lowering intra‑ocular pressure in adult patients.\n\nGNH India supplies Latanoprost/Timolol Elvim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol is a combination ophthalmic therapy used to manage conditions that involve elevated intra‑ocular pressure.\n\nOpen‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.\nOcular hypertension: lowers pressure to prevent progression to glaucoma.\nPost‑surgical ocular pressure control: helps maintain target pressure after glaucoma filtration surgery.

The following adverse reactions have been reported with the combination eye drops.\n\nCommon Side Effects:\n- Eye irritation or burning sensation\n- Blurred vision shortly after instillation\n- Conjunctival hyperemia (redness)\n- Increased eyelash growth\n- Darkening of iris pigmentation\n- Foreign body sensation\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (e.g., angio‑edema)\n- Chest pain or palpitations\n- Shortness of breath or bronchospasm\n- Sudden loss of vision\n- Severe eye pain or inflammation\n- Cardiac arrhythmias

Before prescribing Latanoprost/Timolol, clinicians should consider the following precautions.\n\nCardiovascular assessment: evaluate heart rate and rhythm, especially in patients with bradycardia.\nRespiratory status: avoid in patients with asthma or severe chronic obstructive pulmonary disease.\nSinus node dysfunction: use with caution in patients with sick sinus syndrome.\nPregnancy and lactation: safety not established; weigh potential benefits against risks.\nOcular reaction: discontinue if severe inflammation or allergic response occurs.\nStore at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost/Timolol may interact with other systemic or ocular agents.\n\nMajor Interactions (Avoid):\n- Non‑selective beta‑blockers (e.g., propranolol): additive bradycardia or hypotension.\n- Other prostaglandin analogues: increased risk of ocular hyperemia and iris pigmentation.\n- MAO inhibitors: potential for exaggerated cardiovascular effects.\n\nModerate Interactions (Monitor Closely):\n- Calcium channel blockers: may enhance intra‑ocular pressure‑lowering effect.\n- Inhaled beta‑agonists (e.g., albuterol): may reduce timolol efficacy.\n- Systemic steroids: possible attenuation of prostaglandin effect.